Literature DB >> 31655265

Synthesis of novel N-vinylpyrrolidone/acrylic acid nanoparticles as drug delivery carriers of cisplatin to cancer cells.

Chaiyakarn Pornpitchanarong1, Theerasak Rojanarata1, Praneet Opanasopit1, Tanasait Ngawhirunpat1, Prasopchai Patrojanasophon2.   

Abstract

This study aimed to synthesize novel polymeric nanoparticles (NPs) bound with cisplatin for the treatment of oral cancer. The NPs were synthesized from N-vinylpyrrolidone (NVP) and acrylic acid (AA) using 2 different methods based on a surfactant-free emulsion polymerization reaction. An azo initiator (V50) and bisacrylamide crosslinker were used in the reaction to create the NPs. The morphology, physicochemical characteristics, drug loading, and in vitro release were evaluated. Moreover, the cytotoxicity, death induction mechanism, and in vitro intracellular accumulation of cisplatin in HN22 cells were also investigated. Relatively spherical NPs with negative charge were obtained from both synthesis methods with the size in the range of 136-183 nm. The NPs were bound to cisplatin via coordination bond which was confirmed by FT-IR. The optimal NPs to cisplatin ratio was found to be 1:10 with %entrapment efficiency and loading capacity of 12-18% and 4 mmol/g, respectively. Approximately 47-83% of cisplatin was released from the NPs in 7 days in the presence of chloride ions depending on the pH of the release medium. The novel NPs from both methods were nontoxic to gingival fibroblast cells while the IC50 values of cisplatin-loaded NPs on HN22 cells were just above 20 μg/mL. In addition, the cisplatin-loaded NPs demonstrated a higher percentage in the early apoptotic death mechanism. Higher cellular deposition of cisplatin at the earlier period was obtained by the cisplatin-loaded NPs suggesting a slower but safer cancer-killing effect. Therefore, these novel NPs may be promising nanocarriers of cisplatin for oral cancer treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cisplatin; N-vinylpyrrolidone/acrylic acid nanoparticles; Oral cancer

Mesh:

Substances:

Year:  2019        PMID: 31655265     DOI: 10.1016/j.colsurfb.2019.110566

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  5 in total

Review 1.  Drug Delivery (Nano)Platforms for Oral and Dental Applications: Tissue Regeneration, Infection Control, and Cancer Management.

Authors:  Pooyan Makvandi; Uros Josic; Masoud Delfi; Filippo Pinelli; Vahid Jahed; Emine Kaya; Milad Ashrafizadeh; Atefeh Zarepour; Filippo Rossi; Ali Zarrabi; Tarun Agarwal; Ehsan Nazarzadeh Zare; Matineh Ghomi; Tapas Kumar Maiti; Lorenzo Breschi; Franklin R Tay
Journal:  Adv Sci (Weinh)       Date:  2021-02-05       Impact factor: 16.806

2.  Preactivated-thiolated polyacrylic acid/1-vinyl pyrrolidone nanoparticles as nicotine carriers for smoking cessation.

Authors:  Chaiyakarn Pornpitchanarong; Theerasak Rojanarata; Praneet Opanasopit; Tanasait Ngawhirunpat; Prasopchai Patrojanasophon
Journal:  RSC Adv       Date:  2020-09-10       Impact factor: 4.036

Review 3.  Activity of Povidone in Recent Biomedical Applications with Emphasis on Micro- and Nano Drug Delivery Systems.

Authors:  Ewelina Waleka; Zbigniew Stojek; Marcin Karbarz
Journal:  Pharmaceutics       Date:  2021-05-04       Impact factor: 6.321

4.  Development and Evaluation of Novel Water-Based Drug-in-Adhesive Patches for the Transdermal Delivery of Ketoprofen.

Authors:  Kwanputtha Arunprasert; Chaiyakarn Pornpitchanarong; Theerasak Rojanarata; Tanasait Ngawhirunpat; Praneet Opanasopit; Porawan Aumklad; Prasopchai Patrojanasophon
Journal:  Pharmaceutics       Date:  2021-05-25       Impact factor: 6.321

5.  Synthesis of Polyethylene Glycol Diacrylate/Acrylic Acid Nanoparticles as Nanocarriers for the Controlled Delivery of Doxorubicin to Colorectal Cancer Cells.

Authors:  Yin Yin Myat; Tanasait Ngawhirunpat; Theerasak Rojanarata; Praneet Opanasopit; Mark Bradley; Prasopchai Patrojanasophon; Chaiyakarn Pornpitchanarong
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.